Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes

被引:286
作者
Ishida, T
Harada, M
Wang, XY
Ichihara, M
Irimura, K
Kiwada, H
机构
[1] Univ Tokushima, Grad Sch Pharmaceut Sci, Dept Pharmacokinet & Biopharmaceut, Tokushima 7708505, Japan
[2] Taiho Pharmaceut Co Ltd, Drug Safety Res Lab, Kawaguchi, Tokushima 7710194, Japan
关键词
polyethylene glycol (PEG); accelerated blood clearance (ABC) phenomenon; liposomes; repeated injection; safety evaluation;
D O I
10.1016/j.jconrel.2005.04.003
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
We recently reported that a second dose of polyethylene glycol (PEG) (M.W. 2000)-modified liposomes (mPEG(2000)-liposomes) is rapidly cleared from the blood and accumulates in the liver when injected twice in the same rat or mouse at several-day intervals (referred to as the "accelerated blood clearance (ABC) phenomenon"). In the present study we observed that a high dose (5 mu mol/kg) of conventional liposomes (CL: without a PEG-coating) can induce the same phenomenon, while a low lipid dose (0.001 mu mol/kg) did not. The induction of the phenomenon by mPEG2000-liposomes decreased with increasing first dose (0.001-5 mu mol/kg). We observed a strong inverse relationship between the dose of initially injected PEG(2000)-liposomes and the extent to which the ABC phenomenon was induced: the higher the dose the smaller the phenomenon. Increasing the PEG density at the liposome surface beyond 5 mol% attenuated rather than induced the induction of the phenomenon, but elongation of the PEG chain length up to M.W. 5000, had no effect. In a series of hematological, serum-biochemical and histopathological safety evaluations we observed neither acute toxicity nor any signs of hepatic damage during the induction of the ABC phenomenon. Morphological examination of the liver by transmission electron microscopy (TEM) showed extensive accumulation of the second dose of mPEG(2000)-liposomes in the Kupffer cells, even already after 15 min, suggesting that the PEG liposomes had somehow lost the protective effect of the surface-grafted PEG against rapid clearance. The observations reported in this paper may have a considerable impact on the design and engineering of PEGylated liposomal formulations for use in multiple drug therapy. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:305 / 317
页数:13
相关论文
共 40 条
  • [1] LONG-CIRCULATING (STERICALLY STABILIZED) LIPOSOMES FOR TARGETED DRUG-DELIVERY
    ALLEN, TM
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) : 215 - 220
  • [2] LIPOSOMES CONTAINING SYNTHETIC LIPID DERIVATIVES OF POLY(ETHYLENE GLYCOL) SHOW PROLONGED CIRCULATION HALF-LIVES INVIVO
    ALLEN, TM
    HANSEN, C
    MARTIN, F
    REDEMANN, C
    YAUYOUNG, A
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1066 (01) : 29 - 36
  • [3] BARTLETT GR, 1959, J BIOL CHEM, V234, P466
  • [4] Batist Gerald, 2002, Expert Opin Pharmacother, V3, P1739, DOI 10.1517/14656566.3.12.1739
  • [5] Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions
    Chanan-Khan, A
    Szebeni, J
    Savay, S
    Liebes, L
    Rafique, NM
    Alving, CR
    Muggia, FM
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (09) : 1430 - 1437
  • [6] Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM
    Cheng, TL
    Wu, PY
    Wu, MF
    Chern, JW
    Roffler, SR
    [J]. BIOCONJUGATE CHEMISTRY, 1999, 10 (03) : 520 - 528
  • [7] Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol)
    Chiu, GNC
    Bally, MB
    Mayer, LD
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2001, 1510 (1-2): : 56 - 69
  • [8] LIPOSOMAL DOXORUBICIN-INDUCED TOXICITY - DEPLETION AND IMPAIRMENT OF PHAGOCYTIC-ACTIVITY OF LIVER MACROPHAGES
    DAEMEN, T
    HOFSTEDE, G
    KATE, MTT
    BAKKERWOUDENBERG, IAJM
    SCHERPHOF, GL
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (05) : 716 - 721
  • [9] Dams ETM, 2000, J PHARMACOL EXP THER, V292, P1071
  • [10] Overview of the lipid formulations of amphotericin B
    Dupont, B
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 : 31 - 36